Quick Search
Struma ovarii: Analysis of a single institution
Çiğdem Kılıç1, Dilek Yüksel1, Caner Çakır1, Rıza Dur2, Fulya Kayıkçıoğlu1, Sevgi Koç1, Vakkas Korkmaz1, Yaprak Üstün2, Nurettin Boran11Department of Gynecologic Oncology Surgery, University of Health Sciences, Turkey. Etlik Zübeyde Hanım Maternity and Children’s Training and Research Hospital, İstanbul, Turkey2Department of Gynecology and Obstetrics, University of Health Sciences, Turkey. Etlik Zübeyde Hanım Maternity and Children’s Training and Research Hospital, Ankara, Turkey
INTRODUCTION: The aim of this study was to evaluate the clinicopathological features and oncologic outcomes in patients with struma ovarii (SO) treated and followed up in our hospital.
METHODS: The presented study included 14 patients diagnosed with SO in a single institution for a period of 25 years.
RESULTS: Histopathological diagnosis revealed benign SO in 13 patients and follicular carcinoma in 1 patient with malignant transformation in final pathology reports. The patient with malignant SO was follicular type and stage Ic2. This patient did not receive adjuvant therapy. The median follow-up time of the study cohort was 31 months and ranged between 3 and 134 months. No recurrence was detected in the patient with malignant SO during 44 months of follow-up.
DISCUSSION AND CONCLUSION: Surgical intervention is adequate for treatment in patients with benign SO. For patients with malignant transformation, a conservative surgery may be suitable for fertility sparing. Additionally, staging surgery including retroperitoneal lymph node dissection is recommended for determining adjuvant therapy decisions. Due to the absence of well-defined and precise guidelines for treatment, a multidisciplinary approach is suitable for patients with malignant SO. Therapy modalities should be individualized according to intraoperative and postoperative findings in this patient group.
Manuscript Language: English
